+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Sinusitis (Rhinosinusitis) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • ID: 4830064
  • Drug Pipelines
  • August 2019
  • Region: Global
  • 78 pages
  • VPA Research

FEATURED COMPANIES

  • AmpliPhi Biosciences Corp
  • CRS Bio
  • Intrexon Corp
  • Kyowa Hakko Kirin Co Ltd
  • Merck & Co Inc
  • OptiNose US Inc
High levels of pipeline activity are being observed in Sinusitis (Rhinosinusitis) treatment during 2019. Clinical development activities are being undertaken by more than 15 companies including AmpliPhi Biosciences Corp, AnaptysBio Inc, CRS Bio, GlycoMira Therapeutics Inc, Gossamer Bio Inc and others.

A Significant contribution to the Sinusitis (Rhinosinusitis) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Sinusitis (Rhinosinusitis) pipeline included 18 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Sinusitis (Rhinosinusitis) condition and increased access to investments is encouraging growth of Sinusitis (Rhinosinusitis) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Sinusitis (Rhinosinusitis) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Sinusitis (Rhinosinusitis) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Sinusitis (Rhinosinusitis) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Sinusitis (Rhinosinusitis). Further, orphan drug status, fast track designation, grants awarded and other special status for Sinusitis (Rhinosinusitis) pipeline compounds are also included.

This study was produced independently by the publisher from their proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Sinusitis (Rhinosinusitis) pipeline and formulate effective research and development strategies.

Research Methodology

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Sinusitis (Rhinosinusitis) Pipeline candidates
  • Pre-clinical Phase: Discovery, research, pre-clinical
  • Early Phase: Phase 1 and Phase 2 Sinusitis (Rhinosinusitis) drugs
  • Late phase: Phase 3 and in-approval Sinusitis (Rhinosinusitis) drugs
Companies involved in the Pipeline
  • Company overview
  • Snapshot
  • Sinusitis (Rhinosinusitis) therapeutic treatment activities
Details for each Sinusitis (Rhinosinusitis) drug candidate
  • Snapshot
  • Drug Name
  • Alternative Names
  • Company
  • Originator
  • Phase
  • Molecule Type
  • Orphan Drug Status
  • Drug Overview
  • Mechanism of Action
  • Current Status
  • Trial Details
Other details
  • Pre-clinical trials for each drug candidate
  • Clinical trials for each drug candidate
Recent Sinusitis (Rhinosinusitis) therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AmpliPhi Biosciences Corp
  • CRS Bio
  • Intrexon Corp
  • Kyowa Hakko Kirin Co Ltd
  • Merck & Co Inc
  • OptiNose US Inc
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Sinusitis (Rhinosinusitis)- Disease Overview
2.2 Sinusitis (Rhinosinusitis)- Pipeline Snapshot
2.3 Sinusitis (Rhinosinusitis)- Pipeline Drugs by Phase
2.4 Sinusitis (Rhinosinusitis)- Pipeline Drugs by Company
2.5 Sinusitis (Rhinosinusitis)- Pipeline Drugs by Mechanism of Action

3 Company wise Pipeline Analysis
3.1 AmpliPhi Biosciences Corp Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019
3.2 AnaptysBio Inc Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019
3.3 CRS Bio Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019
3.4 GlycoMira Therapeutics Inc Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019
3.5 Gossamer Bio Inc Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019
3.6 Intrexon Corp Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019
3.7 Knopp Biosciences LLC Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019
3.8 Kyorin Pharmaceutical Co Ltd Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019
3.9 Kyowa Hakko Kirin Co Ltd Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019
3.10 Lyra Therapeutics Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019
3.11 Merck & Co Inc Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019
3.12 Nota Laboratories LLC Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019
3.13 OptiNose US Inc Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019
3.14 Paratek Pharmaceuticals Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019
3.15 Pfizer Inc Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019
3.16 ProclaRx LLC Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019
3.17 Roche Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019
3.18 Therabron Therapeutics Inc Sinusitis (Rhinosinusitis) Drug Pipeline, H2- 2019

4 Phase 1 Pipeline Drug Details
4.1 Sinusitis (Rhinosinusitis)- Phase 1 Drug Details
4.2 Sinusitis (Rhinosinusitis)- Phase 1 Drug Overview
4.3 Sinusitis (Rhinosinusitis)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 Phase 2 Pipeline Drug Details
5.1 Sinusitis (Rhinosinusitis)- Phase 2 Drug Details
5.2 Sinusitis (Rhinosinusitis)- Phase 2 Drug Overview
5.3 Sinusitis (Rhinosinusitis)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 Phase 3 Pipeline Drug Details
6.1 Sinusitis (Rhinosinusitis)- Phase 3 Drug Details
6.2 Sinusitis (Rhinosinusitis)- Phase 3 Drug Overview
6.3 Sinusitis (Rhinosinusitis)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 Pre-clinical Phase Pipeline Drug Details
7.1 Sinusitis (Rhinosinusitis)- Pre-clinical Phase Drug Details
7.2 Sinusitis (Rhinosinusitis)- Pre-clinical Phase Drug Overview
7.3 Sinusitis (Rhinosinusitis)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 Recent News and Developments

9 Appendix
9.1 About the Publisher
9.2 Sources and Research Methodology
Note: Product cover images may vary from those shown
  • AmpliPhi Biosciences Corp
  • AnaptysBio Inc
  • CRS Bio
  • GlycoMira Therapeutics Inc
  • Gossamer Bio Inc
  • Intrexon Corp
  • Knopp Biosciences LLC
  • Kyorin Pharmaceutical Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Lyra Therapeutics
  • Merck & Co Inc
  • Nota Laboratories LLC
  • OptiNose US Inc
  • Paratek Pharmaceuticals
  • Pfizer Inc
  • ProclaRx LLC
  • Roche
  • Therabron Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll